Xeris Biopharma Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Xeris Biopharma Holdings, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue203.07163.91110.2549.5920.44
Cost of Revenue36.8328.6522.6313.329.33
Gross Profit166.24135.2787.6136.2711.11
Operating Expenses
Research & Development25.5622.3420.9725.1618.92
Selling, General & Administrative163.48146.10137.75116.0673.73
Operating Expenses199.88179.28169.55141.7792.65
Operating Income-33.65-44.01-81.94-105.50-81.55
Other Income/Expense
Interest Income5.324.752.580.731.47
Interest Expense30.49-26.61-14.10-7.18-10.66
Other Income/Expense1.710.001.76-0.70-0.01
Income
Income Before Tax-57.10-63.50-96.08-122.73-91.25
Income Tax Expense-2.27-1.25-1.420.00-0.11
Net Income-54.84-62.26-94.66-122.73-91.14
Net Income - Continuous Operations-54.84-62.26-94.66-122.730.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-13.99-31.68-69.70-103.62-80.08
EBIT-26.62-44.01-81.94-105.50-81.55
Depreciation & Amortization10.8412.3312.241.881.47
Earnings Per Share
Basic EPS---1.00-2.00-2.00
Diluted EPS---1.00-2.00-2.00
Basic Shares Outstanding146.77137.67135.6379.0342.64
Diluted Shares Outstanding146.77137.67135.6379.0342.64